Annotation
literal: Daniel Gruen

Annotation
literal: Deborah L. McGuinness

Annotation
literal: Jamie McCusker

Annotation
literal: Oshani Seneviratne

Annotation
literal: 2022-6-08T18:00:00

Annotation
literal: Sabbir M. Rashid

Annotation
literal: The Diabetes Pharmacology Ontology contains the classes needed to describe antihyperglycemic therapies.

Annotation
literal: 2022-12-18T18:00:00

Annotation
literal: Diabetes Pharmacology Ontology

AnnotationAssertion
IRI: http://purl.bioontology.org/ontology/LNC/12228-3
literal: Triglyceride [Mass/volume] in Body fluid

AnnotationAssertion
IRI: http://purl.bioontology.org/ontology/LNC/1518-0
literal: Glucose [Mass/volume] in Serum or Plasma --2 hours post 75 g glucose PO

AnnotationAssertion
IRI: http://purl.bioontology.org/ontology/LNC/1558-6
literal: Fasting glucose [Mass/volume] in Serum or Plasma

AnnotationAssertion
IRI: http://purl.bioontology.org/ontology/LNC/2089-1
literal: Cholesterol in LDL [Mass/volume] in Serum or Plasma

AnnotationAssertion
IRI: http://purl.bioontology.org/ontology/LNC/55548-2
literal: metFORMIN [Moles/volume] in Serum or Plasma

AnnotationAssertion
IRI: http://purl.bioontology.org/ontology/LNC/59261-8
literal: Hemoglobin A1c/Hemoglobin.total in Blood by IFCC protocol

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/CHEBI_167574
literal: semaglutide

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/CHEBI_188719
literal: Ertugliflozin

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/CHEBI_3095
literal: biguanide

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/CHEBI_35526
literal: hypoglycemic agent

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/CHEBI_40237
literal: sitagliptin

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/CHEBI_50122
literal: rosiglitazone

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/CHEBI_50990
literal: thiazolidinediones

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/CHEBI_5383
literal: glimepiride

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/CHEBI_5384
literal: glipizide

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/CHEBI_5441
literal: glyburide

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/CHEBI_64073
literal: exendin-4

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/CHEBI_6801
literal: metformin

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/CHEBI_68610
literal: linagliptin

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/CHEBI_68612
literal: EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/CHEBI_71193
literal: liraglutide

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/CHEBI_71196
literal: glucagon-like peptide-1 receptor agonist

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/CHEBI_71272
literal: saxagliptin

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/CHEBI_72323
literal: alogliptin

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/CHEBI_73273
literal: sodium-glucose transport protein subtype 2 inhibitor

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/CHEBI_73274
literal: canagliflozin

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/CHEBI_76983
literal: N-sulfonylurea

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/CHEBI_8228
literal: pioglitazone

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/CHEBI_82720
literal: empagliflozin

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/CHEBI_85078
literal: dapagliflozin

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/CHEBI_85662
literal: lixisenatide

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/HP_0000009
literal: Functional abnormality of the bladder

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/HP_0012088
literal: Abnormal urinary odor

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/HP_0025142
literal: Constitutional symptom

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/HP_0033072
literal: Abnormal macroscopic urine appearance

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/HP_0100515
literal: Pollakisuria

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/HP_0100749
literal: Chest pain

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C105585
literal: Glucose Measurement

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C105586
literal: Cholesterol Measurement

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C138901
literal: Body Mass Index Finding

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C152328
literal: Semaglutide

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C158136
literal: Empagliflozin

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C16326
literal: Behavior

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C166925
literal: Ertugliflozin

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C166988
literal: Lixisenatide

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C16795
literal: Lifestyle

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C169923
literal: Dulaglutide

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C171128
literal: Non-Neoplastic Endocrine Pancreas Disorder

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C173902
literal: CTRP Clinical Finding

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C17726
literal: Family Medical History

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C18228
literal: Treatment Factor

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C18772
literal: Personal Medical History

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C19160
literal: Occupation or Discipline

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C19591
literal: Diagnostic Factor

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C20047
literal: Diagnostic or Prognostic Factor

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C20181
literal: Conceptual Entity

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C20189
literal: Property or Attribute

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C25193
literal: Occupation

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C25209
literal: Measurement

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C25218
literal: Intervention or Procedure

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C25447
literal: Characteristic

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C25457
literal: Condition

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C26732
literal: Coronary Artery Disease

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C27551
literal: Disorder by Site

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C27993
literal: General Qualifier

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C29073
literal: Glimepiride

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C29074
literal: Glipizide

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C29076
literal: Glyburide

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C2931
literal: Cardiovascular Disorder

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C2938
literal: Cerebrovascular Disorder

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C29711
literal: Anti-diabetic Agent

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C2985
literal: Diabetes Mellitus

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C2991
literal: Disease or Disorder

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C3117
literal: Hypertension

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C3149
literal: Kidney Disorder

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C3283
literal: Obesity

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C3303
literal: Pain

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C3390
literal: Stroke

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C3430
literal: Urinary System Disorder

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C34707
literal: Abnormal Blood Chemistry and Hematology Test Result

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C34707
literal: Hyperlipidemia

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C35719
literal: Genitourinary System Infection

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C35741
literal: Non-Neoplastic Heart Disorder

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C38665
literal: Chest Pain

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C39547
literal: Treatment Efficacy

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C43431
literal: Activity

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C48226
literal: Lack of Efficacy

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C49236
literal: Therapeutic Procedure

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C50791
literal: Urinary Tract Infection

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C53458
literal: Sign

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C54625
literal: History

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C54707
literal: Blood Pressure Finding

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C61612
literal: Metformin

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C62076
literal: Rosiglitazone

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C64812
literal: Triglyceride Measurement

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C65611
literal: Exenatide

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C69088
literal: Cost

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C7057
literal: Disease, Disorder or Finding

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C71633
literal: Pioglitazone

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C73838
literal: Sitagliptin

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C74949
literal: Lipid Measurement

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C75983
literal: Saxagliptin

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C76906
literal: Alogliptin

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C78126
literal: Dapagliflozin

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C80398
literal: Family History of Coronary Artery Disease

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C81229
literal: Alcohol Use History

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C81246
literal: Drug Use History

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C82239
literal: Liraglutide

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C83119
literal: Physical Examination Finding

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C83887
literal: Linagliptin

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C86589
literal: Sedentary Lifestyle

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C88183
literal: Efficacy

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C91018
literal: Canagliflozin

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C9232
literal: Weight Change

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C92744
literal: Blood Glucose Measurement

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C97936
literal: Sulfonylurea Antidiabetic Agent

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C98083
literal: SGLT2 Inhibitor

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C98085
literal: GLP-1 Mimetics

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C98086
literal: Dipeptidyl Peptidase-4 Inhibitor

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C98234
literal: Biguanide Antidiabetic Agent

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/NCIT_C98241
literal: Thiazolidinedione Antidiabetic Agent

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/SYMP_0000012
literal: blurred vision

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/SYMP_0000094
literal: muscle weakness

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/SYMP_0000099
literal: pain

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/SYMP_0000320
literal: vision symptom

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/SYMP_0000352
literal: peripheral muscle weakness

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/SYMP_0000410
literal: neurological and physiological symptom

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/SYMP_0000462
literal: symptom

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/SYMP_0000473
literal: nutrition, metabolism, and development symptom

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/SYMP_0000480
literal: nervous system symptom

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/SYMP_0000485
literal: dysuria

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/SYMP_0000486
literal: urinary system symptom

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/SYMP_0000524
literal: polyphagia

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/SYMP_0000560
literal: polydipsia

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/SYMP_0000563
literal: urinary frequency

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/SYMP_0000565
literal: polyuria

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/SYMP_0000576
literal: chest pain

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/SYMP_0000734
literal: stroke

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/SYMP_0000891
literal: musculoskeletal system symptom

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/SYMP_0019163
literal: eye symptom

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/SYMP_0019169
literal: arthritis

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/SYMP_0019177
literal: fatigue

AnnotationAssertion
abbreviated IRI: dpo:AlcoholUse

AnnotationAssertion
abbreviated IRI: dpo:AlcoholUse
literal: Alcohol Use

AnnotationAssertion
abbreviated IRI: dpo:AlcoholUse
literal: A description of an individual's current and past experience with alcoholic beverage consumption. [Definition Source: NCI]

AnnotationAssertion
abbreviated IRI: dpo:Alogliptin

AnnotationAssertion
abbreviated IRI: dpo:Alogliptin
literal: Alogliptin

AnnotationAssertion
abbreviated IRI: dpo:Alogliptin
literal: A piperidine that is 3-methyl-2,4-dioxo-3,4-dihydropyrimidine carrying additional 2-cyanobenzyl and 3-aminopiperidin-1-yl groups at positions 1 and 2 respectively (the R-enantiomer). Used in the form of its benzoate salt for treatment of type 2 diabetes. [Definition Source: CHEBI]

AnnotationAssertion
abbreviated IRI: dpo:Alogliptin
literal: A selective, orally bioavailable, pyrimidinedione-based inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity. In addition to its effect on glucose levels, alogliptin may inhibit inflammatory responses by preventing the toll-like receptor 4 (TLR-4)-mediated formation of proinflammatory cytokines. [Definition Source: NCI]

AnnotationAssertion
abbreviated IRI: dpo:AntihyperglycemicTreatment
literal: Treatment designed to lower blood sugar levels.

AnnotationAssertion
abbreviated IRI: dpo:AntihyperglycemicTreatment
literal: Antihyperglycemic Treatment

AnnotationAssertion
abbreviated IRI: dpo:AntihyperglycemicTreatment
literal: A drug which lowers the blood glucose level. [Definition Source: CHEBI]

AnnotationAssertion
abbreviated IRI: dpo:Arthritis

AnnotationAssertion
abbreviated IRI: dpo:Arthritis
literal: Arthritis

AnnotationAssertion
abbreviated IRI: dpo:Arthritis
literal: Arthritis is a musculoskeletal system symptom characterized as an inflammation of joints due to infectious, metabolic, or constitutional causes. [ url:http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=Medical&va=arthritis ][Definition Source: SYMP:0019169]

AnnotationAssertion
abbreviated IRI: dpo:AtheroscleroticCardiovascularDiseaseRisk
literal: Risk of cardiovascular disease resulting from atherosclerosis.

AnnotationAssertion
abbreviated IRI: dpo:AtheroscleroticCardiovascularDiseaseRisk
literal: Atherosclerotic Cardiovascular Disease Risk

AnnotationAssertion
abbreviated IRI: dpo:AtheroscleroticCardiovascularDiseaseRisk

AnnotationAssertion
abbreviated IRI: dpo:Behavior

AnnotationAssertion
abbreviated IRI: dpo:Behavior
literal: Behavior

AnnotationAssertion
abbreviated IRI: dpo:Behavior
literal: The actions or reactions of an object or organism, usually in relation to the environment or surrounding world of stimuli. [Definition Source: NCI]

AnnotationAssertion
abbreviated IRI: dpo:Biguanide

AnnotationAssertion
abbreviated IRI: dpo:Biguanide
literal: Biguanide

AnnotationAssertion
abbreviated IRI: dpo:Biguanide
literal: Any antidiabetic agent with the biguanide base structure or phenformin derivatives with antihyperglycemic activity. Biguanide antidiabetic agents activate AMP-activated protein kinase (AMPK) resulting in decreased glucose production in the liver, increased peripheral glucose uptake and improved utilization of glucose. Biguanide-based antidiabetic agents do not cause hypoglycemia. In addition, biguanide antidiabetics decrease absorption of glucose from the gastrointestinal tract. [Definition Source: NCI]

AnnotationAssertion
abbreviated IRI: dpo:BilateralLowerExtremityBurningSensation
literal: Occasional Burning Sensation in Bilateral Lower Extremities

AnnotationAssertion
abbreviated IRI: dpo:BilateralLowerExtremityBurningSensation
literal: Bilateral Lower Extremity Burning Sensation

AnnotationAssertion
abbreviated IRI: dpo:BilateralLowerExtremityBurningSensation

AnnotationAssertion
abbreviated IRI: dpo:BloodGlucoseMeasurement

AnnotationAssertion
abbreviated IRI: dpo:BloodGlucoseMeasurement
literal: Blood Glucose Measurement

AnnotationAssertion
abbreviated IRI: dpo:BloodGlucoseMeasurement
literal: A quantitative measurement for assessing the amount of glucose present in a blood sample. [Definition Source: NCI]

AnnotationAssertion
abbreviated IRI: dpo:BlurredVision

AnnotationAssertion
abbreviated IRI: dpo:BlurredVision
literal: Blurred Vision

AnnotationAssertion
abbreviated IRI: dpo:BlurredVision
literal: A vision symptom that is characterized by a decreased clarity or sharpness in vision, which can be caused by eye conditions myopia or hyperopia. [Definition Source: SYMP:0000012]

AnnotationAssertion
abbreviated IRI: dpo:BodyMassIndexFinding

AnnotationAssertion
abbreviated IRI: dpo:BodyMassIndexFinding
literal: Body Mass Index Finding

AnnotationAssertion
abbreviated IRI: dpo:BodyMassIndexFinding
literal: The result of a body mass index measurement. [Definition Source: NCI]

AnnotationAssertion
abbreviated IRI: dpo:BorderlineHighLDLLevel

AnnotationAssertion
abbreviated IRI: dpo:BorderlineHighLDLLevel
literal: Borderline High LDL Level

AnnotationAssertion
abbreviated IRI: dpo:BorderlineHighLDLLevel

AnnotationAssertion
abbreviated IRI: dpo:BorderlineHighLDLRange
literal: Borderline High LDL Range

AnnotationAssertion
abbreviated IRI: dpo:BorderlineHighLDLRange
literal: 159

AnnotationAssertion
abbreviated IRI: dpo:BorderlineHighLDLRange
literal: 130

AnnotationAssertion
abbreviated IRI: dpo:BorderlineHighTriglycerideLevel

AnnotationAssertion
abbreviated IRI: dpo:BorderlineHighTriglycerideLevel
literal: Borderline High Triglyceride Level

AnnotationAssertion
abbreviated IRI: dpo:BorderlineHighTriglycerideLevel

AnnotationAssertion
abbreviated IRI: dpo:BorderlineHighTriglycerideRange
literal: Borderline High Triglyceride Range

AnnotationAssertion
abbreviated IRI: dpo:BorderlineHighTriglycerideRange
literal: 199

AnnotationAssertion
abbreviated IRI: dpo:BorderlineHighTriglycerideRange
literal: 150

AnnotationAssertion
abbreviated IRI: dpo:Canagliflozin

AnnotationAssertion
abbreviated IRI: dpo:Canagliflozin
literal: Canagliflozin

AnnotationAssertion
abbreviated IRI: dpo:Canagliflozin
literal: A C-glucoside with a thiophene ring that is an orally available inhibitor of sodium-glucose transporter 2 (SGLT2) with antihyperglycemic activity. Canagliflozin is also able to reduce body weight and has a low risk for hypoglycemia. [Definition Source: NCI]

AnnotationAssertion
abbreviated IRI: dpo:CardiovascularDisease

AnnotationAssertion
abbreviated IRI: dpo:CardiovascularDisease
literal: Cardiovascular Disease

AnnotationAssertion
abbreviated IRI: dpo:CardiovascularDisease
literal: A non-neoplastic or neoplastic disorder affecting the heart or the vessels (arteries, veins and lymph vessels). Representative examples of non-neoplastic cardiovascular disorders are endocarditis and hypertension. Representative examples of neoplastic cardiovascular disorders are endocardial myxoma and angiosarcoma. [Definition Source: NCI]

AnnotationAssertion
abbreviated IRI: dpo:CardiovascularEffect
literal: A pharmacotherapy factor related to the heart or blood vessels.

AnnotationAssertion
abbreviated IRI: dpo:CardiovascularEffect
literal: Cardiovascular Effect

AnnotationAssertion
abbreviated IRI: dpo:CardiovascularEffect
literal: Cardiovascular effects are defined as any uncomfortable physical effect that relates to the heart and blood vessels. [Definition Source: url:https://effectindex.com/categories/cardiovascular-effects ]

AnnotationAssertion
abbreviated IRI: dpo:CerebralVascularAccident
literal: A stroke.

AnnotationAssertion
abbreviated IRI: dpo:CerebralVascularAccident
literal: Cerebral Vascular Accident

AnnotationAssertion
abbreviated IRI: dpo:CerebralVascularAccident
literal: A sudden loss of neurological function secondary to hemorrhage or ischemia in the brain parenchyma due to a vascular event. [Definition Source: NCI]

AnnotationAssertion
abbreviated IRI: dpo:CerebralVascularAccident
literal: Stroke is a nervous system symptom characterized by a sudden diminution or loss of consciousness, sensation, and voluntary motion caused by rupture or obstruction (as by a clot) of a blood vessel of the brain. [ url:http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=Medical&va=stroke ][Definition Source: SYMP:0000734]

AnnotationAssertion
abbreviated IRI: dpo:ChestPain

AnnotationAssertion
abbreviated IRI: dpo:ChestPain
literal: Chest Pain

AnnotationAssertion
abbreviated IRI: dpo:ChestPain
literal: An unpleasant sensation characterized by physical discomfort (such as pricking, throbbing, or aching) localized to the chest. [Definition Source: HP:0100749]

AnnotationAssertion
abbreviated IRI: dpo:CholesterolMeasurement

AnnotationAssertion
abbreviated IRI: dpo:CholesterolMeasurement
literal: Cholesterol Measurement

AnnotationAssertion
abbreviated IRI: dpo:CholesterolMeasurement
literal: The determination of the amount of total cholesterol present in a sample. [Definition Source: NCI]

AnnotationAssertion
abbreviated IRI: dpo:Condition

AnnotationAssertion
abbreviated IRI: dpo:Condition
literal: Condition

AnnotationAssertion
abbreviated IRI: dpo:Condition
literal: A state of being, such as a state of health. [Definition Source: NCI]

AnnotationAssertion
abbreviated IRI: dpo:CoronaryArteryDisease

AnnotationAssertion
abbreviated IRI: dpo:CoronaryArteryDisease
literal: Coronary Artery Disease

AnnotationAssertion
abbreviated IRI: dpo:CoronaryArteryDisease
literal: Narrowing of the coronary arteries due to fatty deposits inside the arterial walls. The diagnostic criteria may include documented history of any of the following: documented coronary artery stenosis greater than or equal to 50% (by cardiac catheterization or other modality of direct imaging of the coronary arteries); previous coronary artery bypass surgery (CABG); previous percutaneous coronary intervention (PCI); previous myocardial infarction. (ACC) [Definition Source: NCI]

AnnotationAssertion
abbreviated IRI: dpo:Cost
literal: The expense associated with a therapy.

AnnotationAssertion
abbreviated IRI: dpo:Cost
literal: Cost

AnnotationAssertion
abbreviated IRI: dpo:Cost
literal: The amount paid, charged, or engaged to be paid, for purchasing goods, services and financial instruments. [Definition Source: NCI]

AnnotationAssertion
abbreviated IRI: dpo:DPP4Inhibitor

AnnotationAssertion
abbreviated IRI: dpo:DPP4Inhibitor
literal: DPP-4 Inhibitor

AnnotationAssertion
abbreviated IRI: dpo:DPP4Inhibitor
literal: An EC 3.4.14.* (dipeptidyl- and tripeptidyl-peptidases) inhibitor that specifically inhibits dipeptidyl peptidase-4 (EC 3.4.14.5). [Definition Source: CHEBI]

AnnotationAssertion
abbreviated IRI: dpo:DPP4Inhibitor
literal: Any inhibitor of the proline-specific serine protease dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity. DPP-4 inhibitors bind to DPP-4 and inhibit the breakdown of the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). This prolongs incretin activity, increases postprandial insulin release, decreases glucagon release, delays gastric emptying and lowers blood glucose levels. The risk for hypoglycemia is negligible with the use of DPP-4 inhibitors. [Definition Source: NCI]

AnnotationAssertion
abbreviated IRI: dpo:Dapagliflozin

AnnotationAssertion
abbreviated IRI: dpo:Dapagliflozin
literal: Dapagliflozin

AnnotationAssertion
abbreviated IRI: dpo:Dapagliflozin
literal: A selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor with antihyperglycemic activity. Dapagliflozin selectively and potently inhibits SGLT2 compared to SGLT1, which is the cotransporter of glucose in the gut. [Definition Source: NCI]

AnnotationAssertion
abbreviated IRI: dpo:DiabetesFastingBloodGlucoseLevel

AnnotationAssertion
abbreviated IRI: dpo:DiabetesFastingBloodGlucoseLevel
literal: Diabetes Fasting Blood Glucose Level

AnnotationAssertion
abbreviated IRI: dpo:DiabetesFastingBloodGlucoseLevel
literal: FPG ≥126 mg/dL (7.0 mmol/L). [Definition Source: url:https://doi.org/10.2337/dc22-S002 ]

AnnotationAssertion
abbreviated IRI: dpo:DiabetesFastingBloodGlucoseRange
literal: Diabetes Fasting Blood Glucose Range

AnnotationAssertion
abbreviated IRI: dpo:DiabetesFastingBloodGlucoseRange
literal: 126

AnnotationAssertion
abbreviated IRI: dpo:DiabetesHbA1CLevel

AnnotationAssertion
abbreviated IRI: dpo:DiabetesHbA1CLevel
literal: Diabetes HbA1C Level

AnnotationAssertion
abbreviated IRI: dpo:DiabetesHbA1CLevel
literal: A1C ≥6.5% (48 mmol/mol). [Definition Source: url:https://doi.org/10.2337/dc22-S002 ]

AnnotationAssertion
abbreviated IRI: dpo:DiabetesHbA1CRange
literal: Prediabetes HbA1C Range

AnnotationAssertion
abbreviated IRI: dpo:DiabetesHbA1CRange
literal: 141.25

AnnotationAssertion
abbreviated IRI: dpo:DiabetesMellitus

AnnotationAssertion
abbreviated IRI: dpo:DiabetesMellitus
literal: Diabetes Mellitus

AnnotationAssertion
abbreviated IRI: dpo:DiabetesMellitus
literal: A metabolic disorder characterized by abnormally high blood sugar levels due to diminished production of insulin or insulin resistance/desensitization. [Definition Source: NCI]

AnnotationAssertion
abbreviated IRI: dpo:DiabetesTwoHourBloodGlucoseLevel

AnnotationAssertion
abbreviated IRI: dpo:DiabetesTwoHourBloodGlucoseLevel
literal: Diabetes Two Hour Blood Glucose Level

AnnotationAssertion
abbreviated IRI: dpo:DiabetesTwoHourBloodGlucoseLevel
literal: 2-h PG ≥200 mg/dL (11.1 mmol/L) during OGTT. [Definition Source: url:https://doi.org/10.2337/dc22-S002 ]

AnnotationAssertion
abbreviated IRI: dpo:DiabetesTwoHourBloodGlucoseRange
literal: Diabetes Two Hour Blood Glucose Range

AnnotationAssertion
abbreviated IRI: dpo:DiabetesTwoHourBloodGlucoseRange
literal: 200

AnnotationAssertion
abbreviated IRI: dpo:DiabeticKidneyDiseaseProgression
literal: The progression of diabetic kidney disease.

AnnotationAssertion
abbreviated IRI: dpo:DiabeticKidneyDiseaseProgression
literal: Diabetic Kidney Disease Progression

AnnotationAssertion
abbreviated IRI: dpo:DiabeticKidneyDiseaseProgression
literal: Defined by the presence of diabetes and reduced estimated glomerular filtration rate (eGFR) to <60/ mL/min/1.73 m2, increased albuminuria (>300 mg/24 hours) or both, diabetic kidney disease (DKD) is a progressive disease that affects one in seven individuals worldwide eventuating renal replacement therapy (RRT) and premature death secondary to cardiovascular causes. [Definition Source: url:https://www.ncbi.nlm.nih.gov/books/NBK571719/ ]

AnnotationAssertion
abbreviated IRI: dpo:DiagnosticFactor
literal: A circumstance influencing the dianosis of a disease.

AnnotationAssertion
abbreviated IRI: dpo:DiagnosticFactor
literal: Diagnostic Factor

AnnotationAssertion
abbreviated IRI: dpo:DiagnosticFactor
literal: A biological, physiological, behavioral, or molecular indicator of the presence or predisposition towards development of a specific disease. [Definition Source: NCI]

AnnotationAssertion
abbreviated IRI: dpo:Disease

AnnotationAssertion
abbreviated IRI: dpo:Disease
literal: Disease

AnnotationAssertion
abbreviated IRI: dpo:Disease
literal: Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function. [Definition Source: NCI]

AnnotationAssertion
abbreviated IRI: dpo:DrugUse

AnnotationAssertion
abbreviated IRI: dpo:DrugUse
literal: Drug Use

AnnotationAssertion
abbreviated IRI: dpo:DrugUse
literal: A description of an individual's current and past use and/or abuse of drugs and chemicals. This includes prescription medication, illicit drugs and recreational substances. [Definition Source: NCI]

AnnotationAssertion
abbreviated IRI: dpo:Dulaglutide

AnnotationAssertion
abbreviated IRI: dpo:Dulaglutide
literal: Dulaglutide

AnnotationAssertion
abbreviated IRI: dpo:Dulaglutide
literal: A glucagon-like peptide-1 (GLP-1) receptor agonist that is 90% homologous to native human GLP-1 (7-37) and is composed of a dipeptidyl peptidase-IV-protected GLP-1 analog covalently linked to a human immunoglobulin G4 (IgG4)-Fc heavy chain, with antihyperglycemic activity. Upon administration, dulaglutide binds to and activates GLP-1 receptors, thereby increasing intracellular cyclic AMP (cAMP) in pancreatic beta cells. This increases glucose-dependent insulin release. Dulaglutide also reduces the elevated glucagon secretion by inhibiting alpha cells of the pancreas and slows gastric emptying. Altogether this lowers the postprandial glucose level. GLP-1 is normally secreted by L cells of the gastrointestinal (GI) mucosa in response to a meal to normalize blood glucose levels. [Definition Source: NCI]

AnnotationAssertion
abbreviated IRI: dpo:Dysuria

AnnotationAssertion
abbreviated IRI: dpo:Dysuria
literal: Dysuria

AnnotationAssertion
abbreviated IRI: dpo:Dysuria
literal: A urinary system symptom that is characterized by the difficult, or painful, discharge of urine. [ url:http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=Medical&va=dysuria ][Definition Source: SYMP:0000485]

AnnotationAssertion
abbreviated IRI: dpo:Efficacy

AnnotationAssertion
abbreviated IRI: dpo:Efficacy
literal: Efficacy

AnnotationAssertion
abbreviated IRI: dpo:Efficacy
literal: The probability of benefit to individuals in a defined population from a medical technology applied for a given medical problem under ideal conditions of use. Efficacy is a measure of effect of therapy among appropriate patients in whom treatment is tolerated and effectively administered, under the condition of sufficient patients' compliance, usually determined in randomized trials. [Definition Source: NCI]

AnnotationAssertion
abbreviated IRI: dpo:Empagliflozin

AnnotationAssertion
abbreviated IRI: dpo:Empagliflozin
literal: Empagliflozin

AnnotationAssertion
abbreviated IRI: dpo:Empagliflozin
literal: An orally available competitive inhibitor of sodium-glucose co-transporter 2 (SGLT2; SLC5A2) with antihyperglycemic activity. Upon oral administration, empagliflozin selectively and potently inhibits SGLT2 in the kidneys, thereby suppressing the reabsorption of glucose in the proximal tubule. Inhibition of SGLT2 increases urinary glucose excretion by the kidneys, resulting in a reduction of plasma glucose levels in an insulin-independent manner. Inhibition of SGLT2 in the kidneys also suppresses the renal reabsorption of 1,5-anhydroglucitol (1,5AG). This lowers serum 1,5AG and neutrophil 1,5-anhydroglucitol-6-phosphate (1,5AG6P) levels, which may improve neutropenia and neutrophil dysfunction in patients with glycogen storage disease type Ib (GSD Ib). SGLT2, a transport protein exclusively expressed in the proximal renal tubules, mediates approximately 90% of renal glucose reabsorption from tubular fluid. [Definition Source: NCI]

AnnotationAssertion
abbreviated IRI: dpo:Ertugliflozin

AnnotationAssertion
abbreviated IRI: dpo:Ertugliflozin
literal: Ertugliflozin

AnnotationAssertion
abbreviated IRI: dpo:Ertugliflozin
literal: Ertugliflozin is in a class of medications called sodium-glucose co-transporter 2 (SGLT2) inhibitors. It lowers blood sugar by causing the kidneys to get rid of more glucose in the urine. Ertugliflozin is not used to treat type 1 diabetes (condition in which the body does not produce insulin and, therefore, cannot control the amount of sugar in the blood) or diabetic ketoacidosis (a serious condition that may develop if high blood sugar is not treated). [Definition Source: https://medlineplus.gov/druginfo/meds/a618011.html]

AnnotationAssertion
abbreviated IRI: dpo:Exenatide

AnnotationAssertion
abbreviated IRI: dpo:Exenatide
literal: Exenatide

AnnotationAssertion
abbreviated IRI: dpo:Exenatide
literal: A 39 amino acid peptide and synthetic version of exendin-4, a hormone found in the saliva of the venomous lizard Gila monster, with insulin secretagogue and antihyperglycemic activity. Exenatide is administered subcutaneously and mimics human glucagon-like peptide-1 (GLP-1). Compared to GLP-1, exenatide has a longer half-life of 2.4 hours. [Definition Source: NCI]

AnnotationAssertion
abbreviated IRI: dpo:Exenatide
literal: A bioactive polypeptide of 39 amino acid residues isolated from the saliva of the Gila monster (Heloderma suspectum). High-affinity glucagon-like peptide 1 (GLP-1) receptor agonist (Kd = 136 pM); potently induces cAMP formation without stimulating amylase release in pancreatic acini; potentiates glucose-induced insulin secretion in isolated rat islets; protects against glutamate-induced neurotoxicity. A synthetic version is called exenatide. [Definition Source: CHEBI]

AnnotationAssertion
abbreviated IRI: dpo:ExternalClass
literal: External Class

AnnotationAssertion
abbreviated IRI: dpo:FamilyHistory

AnnotationAssertion
abbreviated IRI: dpo:FamilyHistory
literal: Family History

AnnotationAssertion
abbreviated IRI: dpo:FamilyHistory
literal: A record of a patient's background regarding health and disease events of blood relatives. A patient's family medical history may be important in diagnosing existing conditions. [Definition Source: NCI]

AnnotationAssertion
abbreviated IRI: dpo:FamilyHistoryOfCAD

AnnotationAssertion
abbreviated IRI: dpo:FamilyHistoryOfCAD
literal: Family History of Coronary Artery Disease

AnnotationAssertion
abbreviated IRI: dpo:FamilyHistoryOfCAD
literal: History of a first-degree relative (less than 55 years for male relatives or less than 65 years for female relatives) having had any of the following: coronary artery disease, myocardial infarction, coronary artery bypass graft surgery, percutaneous coronary intervention, or sudden cardiac death without obvious cause. [Definition Source: NCI]

AnnotationAssertion
abbreviated IRI: dpo:FamilyHistoryOfDiabetes

AnnotationAssertion
abbreviated IRI: dpo:FamilyHistoryOfDiabetes
literal: Family History of Diabetes

AnnotationAssertion
abbreviated IRI: dpo:FamilyHistoryOfDiabetes
literal: Having at least one-first-degree relative with diabetes. [Definition Source: url:https://doi.org/10.1111/jdi.12033 ]

AnnotationAssertion
abbreviated IRI: dpo:Fatigue

AnnotationAssertion
abbreviated IRI: dpo:Fatigue
literal: Fatigue

AnnotationAssertion
abbreviated IRI: dpo:Fatigue
literal: Fatigue is a neurological and physiological symptom characterized by a weariness or exhaustion from labor, exertion, or stress. [ url:http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=Medical&va=fatigue ][Definition Source: SYMP:0019177]

AnnotationAssertion
abbreviated IRI: dpo:FoulUrine

AnnotationAssertion
abbreviated IRI: dpo:FoulUrine
literal: Foul Urine

AnnotationAssertion
abbreviated IRI: dpo:FoulUrine
literal: A deviation from the normal odor of the urine. [Definition Source: HP:0012088]

AnnotationAssertion
abbreviated IRI: dpo:FrequentUrination

AnnotationAssertion
abbreviated IRI: dpo:FrequentUrination
literal: Frequent Urination

AnnotationAssertion
abbreviated IRI: dpo:FrequentUrination
literal: Increased frequency of urination. [Definition Source: HP:0100515]

AnnotationAssertion
abbreviated IRI: dpo:GLP1RA

AnnotationAssertion
abbreviated IRI: dpo:GLP1RA
literal: GLP-1 RA

AnnotationAssertion
abbreviated IRI: dpo:GLP1RA
literal: An agonist that binds to and activates glucagon-like peptide-1 (GLP-1) receptors. [Definition Source: CHEBI]

AnnotationAssertion
abbreviated IRI: dpo:GLP1RA
literal: Any of the analogues of the endogenous gastrointestinal hormone glucagon-like peptide-1 (GLP-1) with antihyperglycemic activity. GLP-1 mimetics mimic the activity of GLP-1 and thereby stimulate glucose-dependent secretion of insulin from pancreatic beta cells, suppress glucagon secretion from alpha cells, increase insulin sensitivity and inhibit gastric emptying thereby slowing absorption of nutrients and creating a satiating effect. Altogether, this lowers blood glucose levels. GLP-1 is rapidly inactivated by the enzyme dipeptidyl peptidase-4 (DPP-4). [Definition Source: NCI]

AnnotationAssertion
abbreviated IRI: dpo:Glimepiride

AnnotationAssertion
abbreviated IRI: dpo:Glimepiride
literal: Glimepiride

AnnotationAssertion
abbreviated IRI: dpo:Glimepiride
literal: A long-acting, third-generation sulfonylurea with hypoglycemic activity. Compared to other generations of sulfonylurea compounds, glimepiride is very potent and has a longer duration of action. This agent is metabolized by CYP2C9 and shows peroxisome proliferator-activated receptor gamma (PPARgamma) agonistic activity. [Definition Source: NCI]

AnnotationAssertion
abbreviated IRI: dpo:Glipizide

AnnotationAssertion
abbreviated IRI: dpo:Glipizide
literal: Glipizide

AnnotationAssertion
abbreviated IRI: dpo:Glipizide
literal: A short-acting, second-generation sulfonylurea with hypoglycemic activity. Glipizide is rapidly absorbed, has a very quick onset of action and a short half-life. This agent is extensively metabolized in the liver and the metabolites as well as the unchanged form are excreted in the urine. [Definition Source: NCI]

AnnotationAssertion
abbreviated IRI: dpo:Glipizide
literal: An N-sulfonylurea that is glyburide in which the (5-chloro-2-methoxybenzoyl group is replaced by a (5-methylpyrazin-2-yl)carbonyl group. An oral hypoglycemic agent, it is used in the treatment of type 2 diabetes mellitus. [Definition Source: CHEBI]

AnnotationAssertion
abbreviated IRI: dpo:Glyburide

AnnotationAssertion
abbreviated IRI: dpo:Glyburide
literal: Glyburide

AnnotationAssertion
abbreviated IRI: dpo:Glyburide
literal: A sulfonamide urea derivative with antihyperglycemic activity that can potentially be used to decrease cerebral edema. Upon administration, glyburide binds to and blocks the sulfonylurea receptor type 1 (SUR1) subunit of the ATP-sensitive inwardly-rectifying potassium (K(ATP)) channels on the membranes of pancreatic beta cells. This prevents the inward current flow of positively charged potassium (K+) ions into the cell, and induces a calcium ion (Ca2+) influx through voltage-sensitive calcium channels, which triggers exocytosis of insulin-containing granules. In addition, glyburide also inhibits the SUR1-regulated nonselective cation (NC) Ca-ATP channel, melastatin 4 (transient receptor potential cation channel subfamily M member 4; (TRPM4)), thereby preventing capillary failure and brain swelling. SUR1-TRPM4 channels are formed by co-assembly of SUR1 with TRPM4 in neurons, astrocytes, and capillary endothelium during cerebral ischemia. Upon ischemia-induced ATP depletion, channels open which results in sodium influx, cytotoxic edema formation, capillary fragmentation and necrotic cell death. SUR1-TRPM4 is not expressed in normal, uninjured tissues. [Definition Source: NCI]

AnnotationAssertion
abbreviated IRI: dpo:Glyburide
literal: An N-sulfonylurea that is acetohexamide in which the acetyl group is replaced by a 2-(5-chloro-2-methoxybenzamido)ethyl group. [Definition Source: CHEBI]

AnnotationAssertion
abbreviated IRI: dpo:HeartFailureRisk
literal: Risk of heart failure.

AnnotationAssertion
abbreviated IRI: dpo:HeartFailureRisk
literal: Heart Failure Risk

AnnotationAssertion
abbreviated IRI: dpo:HeartFailureRisk

AnnotationAssertion
abbreviated IRI: dpo:HighCost
literal: Relatively expensive.

AnnotationAssertion
abbreviated IRI: dpo:HighCost
literal: High Cost

AnnotationAssertion
abbreviated IRI: dpo:HighCost

AnnotationAssertion
abbreviated IRI: dpo:HighEfficacy
literal: A high capacity to bring about a desired effect.

AnnotationAssertion
abbreviated IRI: dpo:HighEfficacy
literal: High Efficacy

AnnotationAssertion
abbreviated IRI: dpo:HighEfficacy

AnnotationAssertion
abbreviated IRI: dpo:HighLDLLevel

AnnotationAssertion
abbreviated IRI: dpo:HighLDLLevel
literal: High LDL Level

AnnotationAssertion
abbreviated IRI: dpo:HighLDLLevel

AnnotationAssertion
abbreviated IRI: dpo:HighLDLRange
literal: High LDL Range

AnnotationAssertion
abbreviated IRI: dpo:HighLDLRange
literal: 189

AnnotationAssertion
abbreviated IRI: dpo:HighLDLRange
literal: 160

AnnotationAssertion
abbreviated IRI: dpo:HighTriglycerideLevel

AnnotationAssertion
abbreviated IRI: dpo:HighTriglycerideLevel
literal: High Triglyceride Level

AnnotationAssertion
abbreviated IRI: dpo:HighTriglycerideLevel

AnnotationAssertion
abbreviated IRI: dpo:HighTriglycerideRange
literal: High Triglyceride Range

AnnotationAssertion
abbreviated IRI: dpo:HighTriglycerideRange
literal: 499

AnnotationAssertion
abbreviated IRI: dpo:HighTriglycerideRange
literal: 200

AnnotationAssertion
abbreviated IRI: dpo:History

AnnotationAssertion
abbreviated IRI: dpo:History
literal: History

AnnotationAssertion
abbreviated IRI: dpo:History
literal: The aggregate of past events; the continuum of events occurring in succession leading from the past to the present; a record or narrative description of past events. [Definition Source: NCI]

AnnotationAssertion
abbreviated IRI: dpo:Hyperlipidemia

AnnotationAssertion
abbreviated IRI: dpo:Hyperlipidemia
literal: Hyperlipidemia

AnnotationAssertion
abbreviated IRI: dpo:Hyperlipidemia
literal: Elevated levels of lipids in the blood. [Definition Source: NCI]

AnnotationAssertion
abbreviated IRI: dpo:Hypertension

AnnotationAssertion
abbreviated IRI: dpo:Hypertension
literal: Hypertension

AnnotationAssertion
abbreviated IRI: dpo:Hypertension
literal: Blood pressure that is abnormally high. [Definition Source: NCI]

AnnotationAssertion
abbreviated IRI: dpo:HypoglycemiaRisk
literal: The possiblility of lowering blood sugar below the normal range.

AnnotationAssertion
abbreviated IRI: dpo:HypoglycemiaRisk
literal: Hypoglycemia Risk

AnnotationAssertion
abbreviated IRI: dpo:HypoglycemiaRisk
literal: The most important risk factor for the occurrence of hypoglycemia is the aggressiveness of therapy applied to achieve glycemic control. [Definition Source: url:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3784865/ ]

AnnotationAssertion
abbreviated IRI: dpo:IncreasedASCVDRisk
literal: Potential to increase the risk of cardiovascular disease resulting from atherosclerosis.

AnnotationAssertion
abbreviated IRI: dpo:IncreasedASCVDRisk
literal: Increased ASCVD Risk

AnnotationAssertion
abbreviated IRI: dpo:IncreasedASCVDRisk

AnnotationAssertion
abbreviated IRI: dpo:IncreasedDKDRisk
literal: Potential to increase the risk or progression of diabetic kidney disease.

AnnotationAssertion
abbreviated IRI: dpo:IncreasedDKDRisk
literal: Increased Diabetic Kidney Disease Risk

AnnotationAssertion
abbreviated IRI: dpo:IncreasedDKDRisk

AnnotationAssertion
abbreviated IRI: dpo:IncreasedHeartFailureRisk
literal: Potential to increase the risk of heart failure.

AnnotationAssertion
abbreviated IRI: dpo:IncreasedHeartFailureRisk
literal: Increased Heart Failure Risk

AnnotationAssertion
abbreviated IRI: dpo:IncreasedHeartFailureRisk

AnnotationAssertion
abbreviated IRI: dpo:IntermediateEfficacy
literal: An intermediate capacity to bring about a desired effect.

AnnotationAssertion
abbreviated IRI: dpo:IntermediateEfficacy
literal: Intermediate Efficacy

AnnotationAssertion
abbreviated IRI: dpo:IntermediateEfficacy

AnnotationAssertion
abbreviated IRI: dpo:KnownHypoglycemiaRisk
literal: A known association with the lowering of blood sugar below the normal range.

AnnotationAssertion
abbreviated IRI: dpo:KnownHypoglycemiaRisk
literal: Known Hypoglycemia Risk

AnnotationAssertion
abbreviated IRI: dpo:KnownHypoglycemiaRisk

AnnotationAssertion
abbreviated IRI: dpo:Linagliptin

AnnotationAssertion
abbreviated IRI: dpo:Linagliptin
literal: Linagliptin

AnnotationAssertion
abbreviated IRI: dpo:Linagliptin
literal: A potent, orally bioavailable dihydropurinedione-based inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity. The inhibition of DPP-4 by linagliptin appears to be longer lasting than that by some other DPP-4 inhibitors tested. [Definition Source: NCI]

AnnotationAssertion
abbreviated IRI: dpo:Linagliptin
literal: A xanthine that is 7H-xanthine bearing (4-methylquinazolin-2-yl)methyl, methyl, but-2-yn-1-yl and 3-aminopiperidin-1-yl substituents at positions 1, 3, 7 and 8 respectively (the R-enantiomer). Used for treatment of type II diabetes. [Definition Source: CHEBI]

AnnotationAssertion
abbreviated IRI: dpo:Liraglutide

AnnotationAssertion
abbreviated IRI: dpo:Liraglutide
literal: Liraglutide

AnnotationAssertion
abbreviated IRI: dpo:Liraglutide
literal: A long-acting, fatty acylated glucagon-like peptide-1 (GLP-1) analog administered subcutaneously, with antihyperglycemic activity. Liraglutide's prolonged action and half-life of 11-15 hours are attributed to the attachment of the fatty acid palmitic acid to GLP-1 that reversibly binds to albumin. Albumin binding protects liraglutide from immediate degradation and elimination and causes GLP-1 to be released from abumin in a slow and consistent manner. This agent may cause thyroid C-cell tumors and increases the risk of acute pancreatitis. [Definition Source: NCI]

AnnotationAssertion
abbreviated IRI: dpo:Lixisenatide

AnnotationAssertion
abbreviated IRI: dpo:Lixisenatide
literal: Lixisenatide

AnnotationAssertion
abbreviated IRI: dpo:Lixisenatide
literal: A forty-four membered polypeptide consisting of L-His, Gly, L-Glu, Gly, L-Thr, L-Phe, L-Thr, L-Ser, L-Asp, L-Leu, L-Ser, L-Lys, L-Gln, L-Met, L-Glu, L-Glu, L-Glu, L-Ala, L-Val, L-Arg, L-Leu, L-Phe, L-Ile, L-Glu, L-Trp, L-Leu, L-Lys, L-Asn, Gly, Gly, LPro, L-Ser, L-Ser, Gly, L-Ala, L-Pro, L-Pro, L-Ser, L-Lys, L-Lys, L-Lys, L-Lys, L-Lys, and L-Lys-NH2 residues joined in sequence. Used as an adjunct to diet and exercise for the treatment of adults with type II diabetes. [Definition Source: CHEBI]

AnnotationAssertion
abbreviated IRI: dpo:LowCost
literal: Relatively inexpensive.

AnnotationAssertion
abbreviated IRI: dpo:LowCost
literal: Low Cost

AnnotationAssertion
abbreviated IRI: dpo:LowCost

AnnotationAssertion
abbreviated IRI: dpo:LowEfficacy
literal: A low capacity to bring about a desired effect.

AnnotationAssertion
abbreviated IRI: dpo:LowEfficacy
literal: Low Efficacy

AnnotationAssertion
abbreviated IRI: dpo:LowEfficacy
literal: The lack of expected or desired effect related to a therapy. [Definition Source: NCI]

AnnotationAssertion
abbreviated IRI: dpo:Metformin

AnnotationAssertion
abbreviated IRI: dpo:Metformin
literal: Metformin

AnnotationAssertion
abbreviated IRI: dpo:Metformin
literal: An agent belonging to the biguanide class of antidiabetics with antihyperglycemic activity. Metformin is associated with a very low incidence of lactic acidosis. This agent helps reduce LDL cholesterol and triglyceride levels, and is not associated with weight gain, and prevents the cardiovascular complications of diabetes. Metformin is not metabolized and is excreted unchanged by the kidneys. [Definition Source: NCI]

AnnotationAssertion
abbreviated IRI: dpo:MusculoskeletalSystemSymptom
literal: A symptom involving the musculoskeletal system.

AnnotationAssertion
abbreviated IRI: dpo:MusculoskeletalSystemSymptom
literal: Musculoskeletal System Symptom

AnnotationAssertion
abbreviated IRI: dpo:MusculoskeletalSystemSymptom
literal: Musculoskeletal symptoms are defined as pain in the muscles, tendons, and nerves arising from repetitive, continuous, and unnatural movements. These symptoms can be expressed in various areas of the body and affect the quality of life by causing difficulties in performing occupational tasks and activities of daily living (ADL). [Definition Source: url:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3567324/ ]

AnnotationAssertion
abbreviated IRI: dpo:NearOptimalLDLLevel

AnnotationAssertion
abbreviated IRI: dpo:NearOptimalLDLLevel
literal: Near Optimal LDL Level

AnnotationAssertion
abbreviated IRI: dpo:NearOptimalLDLLevel

AnnotationAssertion
abbreviated IRI: dpo:NearOptimalLDLRange
literal: Near Optimal LDL Range

AnnotationAssertion
abbreviated IRI: dpo:NearOptimalLDLRange
literal: 129

AnnotationAssertion
abbreviated IRI: dpo:NearOptimalLDLRange
literal: 100

AnnotationAssertion
abbreviated IRI: dpo:NervousSystemSymptom

AnnotationAssertion
abbreviated IRI: dpo:NervousSystemSymptom
literal: Nervous System Symptom

AnnotationAssertion
abbreviated IRI: dpo:NervousSystemSymptom

AnnotationAssertion
abbreviated IRI: dpo:NeurologicalAndPhysiologicalSymptom

AnnotationAssertion
abbreviated IRI: dpo:NeurologicalAndPhysiologicalSymptom
literal: Neurological and Physiological Symptom

AnnotationAssertion
abbreviated IRI: dpo:NeurologicalAndPhysiologicalSymptom

AnnotationAssertion
abbreviated IRI: dpo:NeutralASCVDRisk
literal: Minimal effect on reducing or increasing the risk of cardiovascular disease resulting from atherosclerosis.

AnnotationAssertion
abbreviated IRI: dpo:NeutralASCVDRisk
literal: Neutral ASCVD Risk

AnnotationAssertion
abbreviated IRI: dpo:NeutralASCVDRisk

AnnotationAssertion
abbreviated IRI: dpo:NeutralDKDRisk
literal: Minimal effect on reducing or increasing the risk or progression of diabetic kidney disease.

AnnotationAssertion
abbreviated IRI: dpo:NeutralDKDRisk
literal: Neutral Diabetic Kidney Disease Risk

AnnotationAssertion
abbreviated IRI: dpo:NeutralDKDRisk

AnnotationAssertion
abbreviated IRI: dpo:NeutralHeartFailureRisk
literal: Minimal effect on reducing or increasing the risk of heart failure.

AnnotationAssertion
abbreviated IRI: dpo:NeutralHeartFailureRisk
literal: Neutral Heart Failure Risk

AnnotationAssertion
abbreviated IRI: dpo:NeutralHeartFailureRisk

AnnotationAssertion
abbreviated IRI: dpo:NeutralWeightChange
literal: The lack of an effect on the capacity for an increase or decrease in the weight of an individual.

AnnotationAssertion
abbreviated IRI: dpo:NeutralWeightChange
literal: Neutral Weight Change

AnnotationAssertion
abbreviated IRI: dpo:NeutralWeightChange

AnnotationAssertion
abbreviated IRI: dpo:NoKnownHypoglycemiaRisk
literal: No known association with the lowering of blood sugar below the normal range.

AnnotationAssertion
abbreviated IRI: dpo:NoKnownHypoglycemiaRisk
literal: No Known Hypoglycemia Risk

AnnotationAssertion
abbreviated IRI: dpo:NoKnownHypoglycemiaRisk

AnnotationAssertion
abbreviated IRI: dpo:NormalTriglycerideLevel

AnnotationAssertion
abbreviated IRI: dpo:NormalTriglycerideLevel
literal: Normal Triglyceride Level

AnnotationAssertion
abbreviated IRI: dpo:NormalTriglycerideLevel

AnnotationAssertion
abbreviated IRI: dpo:NormalTriglycerideRange
literal: Normal Triglyceride Range

AnnotationAssertion
abbreviated IRI: dpo:NormalTriglycerideRange
literal: 149

AnnotationAssertion
abbreviated IRI: dpo:NormalWeight
literal: 18.5<BMI<24.9

AnnotationAssertion
abbreviated IRI: dpo:NormalWeight
literal: Normal Weight

AnnotationAssertion
abbreviated IRI: dpo:NormalWeight
literal: BMI greater than or equal to 18.5 to 24.9 kg/m^2 [Definition Source: url:https://www.ncbi.nlm.nih.gov/books/NBK541070/ ]

AnnotationAssertion
abbreviated IRI: dpo:NormalWeightBMIRange
literal: Normal Weight BMI Range

AnnotationAssertion
abbreviated IRI: dpo:NormalWeightBMIRange
literal: 24.9

AnnotationAssertion
abbreviated IRI: dpo:NormalWeightBMIRange
literal: 18.5

AnnotationAssertion
abbreviated IRI: dpo:NutritionMetabolismAndDevelopmentSymptom
literal: A symptom involving the nutrition, metabolism, and/or development system.

AnnotationAssertion
abbreviated IRI: dpo:NutritionMetabolismAndDevelopmentSymptom
literal: Nutrition Metabolism and Development Symptom

AnnotationAssertion
abbreviated IRI: dpo:NutritionMetabolismAndDevelopmentSymptom
literal: Symptoms concerning nutrition metabolism and development [include:] A disorder characterized by a loss of appetite; An abnormal loss of the appetite for food. Anorexia can be caused by cancer, aids, a mental disorder (i.e., anorexia nervosa), or other diseases; Clinical manifestation consisting of a physiopathological lack or loss of appetite accompanied by an aversion to food and the inability to eat; Loss of appetite; The lack or loss of appetite accompanied by an aversion to food and the inability to eat. It is the defining characteristic of the disorder anorexia nervosa. [Definition Source: url:http://www.icd9data.com/2013/Volume1/780-799/780-789/783/default.htm ]

AnnotationAssertion
abbreviated IRI: dpo:Obese
literal: 30<BMI

AnnotationAssertion
abbreviated IRI: dpo:Obese
literal: Obese

AnnotationAssertion
abbreviated IRI: dpo:Obese
literal: Having a high amount of body fat (body mass index [BMI] of 30 or more). [Definition Source: NCI]

AnnotationAssertion
abbreviated IRI: dpo:Obese
literal: The quantification of weight/height relationships above a certain threshold that classes an individual as overweight. This threshold may vary based on an individual's ethnicity but is commonly considered to correspond in European populations to a BMI > 30. [Definition Source: EFO:0007041]

AnnotationAssertion
abbreviated IRI: dpo:ObeseBMIRange
literal: Obese BMI Range

AnnotationAssertion
abbreviated IRI: dpo:ObeseBMIRange
literal: 30

AnnotationAssertion
abbreviated IRI: dpo:Occupation

AnnotationAssertion
abbreviated IRI: dpo:Occupation
literal: Occupation

AnnotationAssertion
abbreviated IRI: dpo:Occupation
literal: The principal activity that a person does to earn money. [Definition Source: NCI]

AnnotationAssertion
abbreviated IRI: dpo:OptimalLDLLevel

AnnotationAssertion
abbreviated IRI: dpo:OptimalLDLLevel
literal: Optimal LDL Level

AnnotationAssertion
abbreviated IRI: dpo:OptimalLDLLevel

AnnotationAssertion
abbreviated IRI: dpo:OptimalLDLRange
literal: Optimal LDL Range

AnnotationAssertion
abbreviated IRI: dpo:OptimalLDLRange
literal: 100

AnnotationAssertion
abbreviated IRI: dpo:Overweight
literal: 25<BMI<30

AnnotationAssertion
abbreviated IRI: dpo:Overweight
literal: Overweight

AnnotationAssertion
abbreviated IRI: dpo:Overweight
literal: The quantification of weight/height relationships above a certain threshold that classes an individual as overweight. This threshold may vary based on an individual's ethnicity but is commonly considered to correspond in European populations to a 25<BMI<30. [Definition Source: EFO:0005935]

AnnotationAssertion
abbreviated IRI: dpo:OverweightBMIRange
literal: Overweight BMI Range

AnnotationAssertion
abbreviated IRI: dpo:OverweightBMIRange
literal: 30

AnnotationAssertion
abbreviated IRI: dpo:OverweightBMIRange
literal: 25

AnnotationAssertion
abbreviated IRI: dpo:Pain

AnnotationAssertion
abbreviated IRI: dpo:Pain
literal: Pain

AnnotationAssertion
abbreviated IRI: dpo:Pain
literal: A sensation perception where there is an unpleasant sensation that usually indicates the body is threatened or damaged. The sensation may be sharp or dull, short-lived or chronic, intermittent or continual, confined to one area or spread over the entire body. [ url:http://www.nationalpainfoundation.org/MyTreatment/articles/Cancer_PainDefinitions.asp ][Definition Source: SYMP:0000576]

AnnotationAssertion
abbreviated IRI: dpo:PatientCharacteristic

AnnotationAssertion
abbreviated IRI: dpo:PatientCharacteristic
literal: Patient Characteristic

AnnotationAssertion
abbreviated IRI: dpo:PatientCharacteristic
literal: The distinguishing qualities or prominent aspect of a person. [Definition Source: NCI]

AnnotationAssertion
abbreviated IRI: dpo:PeripheralNeuropathy

AnnotationAssertion
abbreviated IRI: dpo:PeripheralNeuropathy
literal: Peripheral Neuropathy

AnnotationAssertion
abbreviated IRI: dpo:PeripheralNeuropathy
literal: Peripheral neuropathy refers to the many conditions that involve damage to the peripheral nervous system, the vast communication network that sends signals between the central nervous system (the brain and spinal cord) and all other parts of the body. [Definition Source: url:https://www.ninds.nih.gov/peripheral-neuropathy-fact-sheet ]

AnnotationAssertion
abbreviated IRI: dpo:PersonalHistory

AnnotationAssertion
abbreviated IRI: dpo:PersonalHistory
literal: Personal History

AnnotationAssertion
abbreviated IRI: dpo:PersonalHistory
literal: A record of a patient's background regarding health and the occurrence of disease events of the individual. In addition, personal medical history may be a variable in epidemiologic studies. [Definition Source: NCI]

AnnotationAssertion
abbreviated IRI: dpo:PersonalHistoryOfFebrileStates

AnnotationAssertion
abbreviated IRI: dpo:PersonalHistoryOfFebrileStates
literal: Personal History of Febrile States

AnnotationAssertion
abbreviated IRI: dpo:PersonalHistoryOfFebrileStates
literal: Febrile seizures are defined as events in infancy or childhood that usually occur between three months and five years of age and are associated with a fever, but without evidence of intracranial infection or a defined cause for the seizure. [Definition Source: url:https://www.aafp.org/pubs/afp/issues/2008/1115/p1199.html ]

AnnotationAssertion
abbreviated IRI: dpo:PersonalHistoryOfGestationalDiabetes

AnnotationAssertion
abbreviated IRI: dpo:PersonalHistoryOfGestationalDiabetes
literal: Personal History of Gestational Diabetes

AnnotationAssertion
abbreviated IRI: dpo:PersonalHistoryOfGestationalDiabetes
literal: Gestational diabetes mellitus (GDM), defined as glucose intolerance that is first recognized during pregnancy, is associated with maternal obesity and confers a 4‐ to 7‐fold greater risk of incident type 2 diabetes (DM), and increased risk of developing the metabolic syndrome (MetS) in midlife. In addition, a history of GDM among nondiabetic women is characterized by elevations in fasting glucose and insulin concentrations, as well as dyslipidemia and greater inflammation in the absence of the MetS. [Definition Source: url:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4187501/ ]

AnnotationAssertion
abbreviated IRI: dpo:PharmacotherapyFactor
literal: A circumstance influencing the treatment of a disease through the use or recommendation of one or more drugs.

AnnotationAssertion
abbreviated IRI: dpo:PharmacotherapyFactor
literal: Pharmacotherapy Factor

AnnotationAssertion
abbreviated IRI: dpo:PharmacotherapyFactor
literal: Therapy-related factors identified include: route of administration, treatment complexity, duration of treatment period, medication side effects, degree of behavioral change required, taste of medication and requirement for drug storage. [Definition Source: url:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2503662/ ]

AnnotationAssertion
abbreviated IRI: dpo:Pioglitazone

AnnotationAssertion
abbreviated IRI: dpo:Pioglitazone
literal: Pioglitazone

AnnotationAssertion
abbreviated IRI: dpo:Pioglitazone
literal: A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity. [Definition Source: CHEBI]

AnnotationAssertion
abbreviated IRI: dpo:Pioglitazone
literal: An orally-active thiazolidinedione with antidiabetic properties and potential antineoplastic activity. Pioglitazone activates peroxisome proliferator-activated receptor gamma (PPAR-gamma), a ligand-activated transcription factor, thereby inducing cell differentiation and inhibiting cell growth and angiogenesis. This agent also modulates the transcription of insulin-responsive genes, inhibits macrophage and monocyte activation, and stimulates adipocyte differentiation. [Definition Source: NCI]

AnnotationAssertion
abbreviated IRI: dpo:Polydipsia

AnnotationAssertion
abbreviated IRI: dpo:Polydipsia
literal: Polydipsia

AnnotationAssertion
abbreviated IRI: dpo:Polydipsia
literal: Polydipsia is a nutrition, metabolism, and development symptom characterized by an excessive or abnormal thirst. [ url:http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=Medical&va=polydipsia ][Definition Source: SYMP:0000560]

AnnotationAssertion
abbreviated IRI: dpo:Polyphagia

AnnotationAssertion
abbreviated IRI: dpo:Polyphagia
literal: Polyphagia

AnnotationAssertion
abbreviated IRI: dpo:Polyphagia
literal: Polyphagia is a nutrition, metabolism, and development symptom characterized by an excessive appetite or eating. [ url:http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=Medical&va=polyphagia ][Definition Source: SYMP:0000524]

AnnotationAssertion
abbreviated IRI: dpo:Polyuria

AnnotationAssertion
abbreviated IRI: dpo:Polyuria
literal: Polyuria

AnnotationAssertion
abbreviated IRI: dpo:Polyuria
literal: A urinary system symptom that is characterized by the excessive secretion of urine. [ url:http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=Medical&va=polyuria ][Definition Source: SYMP:0000565]

AnnotationAssertion
abbreviated IRI: dpo:PotentialASCVDBenefit
literal: Potential to reduce the risk of cardiovascular disease resulting from atherosclerosis.

AnnotationAssertion
abbreviated IRI: dpo:PotentialASCVDBenefit
literal: Potential ASCVD Benefit

AnnotationAssertion
abbreviated IRI: dpo:PotentialASCVDBenefit

AnnotationAssertion
abbreviated IRI: dpo:PotentialDKDBenefit
literal: Potential to decrease the risk or progression of diabetic kidney disease.

AnnotationAssertion
abbreviated IRI: dpo:PotentialDKDBenefit
literal: Potential Diabetic Kidney Disease Benefit

AnnotationAssertion
abbreviated IRI: dpo:PotentialDKDBenefit

AnnotationAssertion
abbreviated IRI: dpo:PotentialHeartFailureBenefit
literal: Potential to decrease the risk of heart failure.

AnnotationAssertion
abbreviated IRI: dpo:PotentialHeartFailureBenefit
literal: Potential Heart Failure Benefit

AnnotationAssertion
abbreviated IRI: dpo:PotentialHeartFailureBenefit

AnnotationAssertion
abbreviated IRI: dpo:PrediabetesFastingBloodGlucoseLevel
literal: impaired fasting glucose

AnnotationAssertion
abbreviated IRI: dpo:PrediabetesFastingBloodGlucoseLevel
literal: Prediabetes Fasting Blood Glucose Level

AnnotationAssertion
abbreviated IRI: dpo:PrediabetesFastingBloodGlucoseLevel
literal: FPG 100 mg/dL (5.6 mmol/L) to 125 mg/dL (6.9 mmol/L). [Definition Source: url:https://doi.org/10.2337/dc22-S002 ]

AnnotationAssertion
abbreviated IRI: dpo:PrediabetesFastingBloodGlucoseRange
literal: Prediabetes Fasting Blood Glucose Range

AnnotationAssertion
abbreviated IRI: dpo:PrediabetesFastingBloodGlucoseRange
literal: 125

AnnotationAssertion
abbreviated IRI: dpo:PrediabetesFastingBloodGlucoseRange
literal: 100

AnnotationAssertion
abbreviated IRI: dpo:PrediabetesHbA1CLevel

AnnotationAssertion
abbreviated IRI: dpo:PrediabetesHbA1CLevel
literal: Prediabetes HbA1C Level

AnnotationAssertion
abbreviated IRI: dpo:PrediabetesHbA1CLevel
literal: A1C 5.7–6.4% (39–47 mmol/mol). [Definition Source: url:https://doi.org/10.2337/dc22-S002 ]

AnnotationAssertion
abbreviated IRI: dpo:PrediabetesHbA1CRange
literal: Prediabetes HbA1C Range

AnnotationAssertion
abbreviated IRI: dpo:PrediabetesHbA1CRange
literal: 138.62

AnnotationAssertion
abbreviated IRI: dpo:PrediabetesHbA1CRange
literal: 117.58

AnnotationAssertion
abbreviated IRI: dpo:PrediabetesTwoHourBloodGlucoseLevel
literal: impaired glucose tolerance

AnnotationAssertion
abbreviated IRI: dpo:PrediabetesTwoHourBloodGlucoseLevel
literal: Prediabetes Two Hour Blood Glucose Level

AnnotationAssertion
abbreviated IRI: dpo:PrediabetesTwoHourBloodGlucoseLevel
literal: 2-h PG during 75-g OGTT 140 mg/dL (7.8 mmol/L) to 199 mg/dL (11.0 mmol/L). [Definition Source: url:https://doi.org/10.2337/dc22-S002 ]

AnnotationAssertion
abbreviated IRI: dpo:PrediabetesTwoHourBloodGlucoseRange
literal: Prediabetes Two Hour Blood Glucose Range

AnnotationAssertion
abbreviated IRI: dpo:PrediabetesTwoHourBloodGlucoseRange
literal: 199

AnnotationAssertion
abbreviated IRI: dpo:PrediabetesTwoHourBloodGlucoseRange
literal: 140

AnnotationAssertion
abbreviated IRI: dpo:RenalDisease
literal: Disease associated with kidneys, typically chronic kidney disease.

AnnotationAssertion
abbreviated IRI: dpo:RenalDisease
literal: Renal Disease

AnnotationAssertion
abbreviated IRI: dpo:RenalDisease
literal: A neoplastic or non-neoplastic condition affecting the kidney. Representative examples of non-neoplastic conditions include glomerulonephritis and nephrotic syndrome. Representative examples of neoplastic conditions include benign processes (e.g., renal lipoma and renal fibroma) and malignant processes (e.g., renal cell carcinoma and renal lymphoma). [Definition Source: NCI]

AnnotationAssertion
abbreviated IRI: dpo:RenalDosingConsideration
literal: Drug dosage considerations related to the effect on the kidneys.

AnnotationAssertion
abbreviated IRI: dpo:RenalDosingConsideration
literal: Renal Dosing Consideration

AnnotationAssertion
abbreviated IRI: dpo:RenalDosingConsideration

AnnotationAssertion
abbreviated IRI: dpo:RenalEffect
literal: A pharmacotherapy factor related to the kidneys.

AnnotationAssertion
abbreviated IRI: dpo:RenalEffect
literal: Renal Effect

AnnotationAssertion
abbreviated IRI: dpo:RenalEffect

AnnotationAssertion
abbreviated IRI: dpo:Rosiglitazone

AnnotationAssertion
abbreviated IRI: dpo:Rosiglitazone
literal: Rosiglitazone

AnnotationAssertion
abbreviated IRI: dpo:Rosiglitazone
literal: An agent belonging to the glitazone class of antidiabetic agents with antihyperglycemic and anti-inflammatory activities. In addition to its selective affinity for peroxisome proliferator-activated receptor (PPAR) gamma and its ability to lower blood glucose levels, rosiglitazone also exerts anti-inflammatory activity through its ability to inhibit nuclear factor-kappaB (NF-KB) activity and increase I-kappaB levels. In addition, rosiglitazone may cause fluid retention and may worsen congestive heart failure. This agent is also associated with an increased risk of heart attacks. [Definition Source: NCI]

AnnotationAssertion
abbreviated IRI: dpo:SGLT2Inhibitor

AnnotationAssertion
abbreviated IRI: dpo:SGLT2Inhibitor
literal: SGLT2 Inhibitor

AnnotationAssertion
abbreviated IRI: dpo:SGLT2Inhibitor
literal: Any inhibitor of the sodium-glucose co-transporter subtype 2 (SGLT2) with antihyperglycemic activity. By binding to and blocking SGLT2, these inhibitors suppress reabsorption of glucose in the proximal tubule within the kidneys and thereby enhancing urinary excretion of glucose. This eventually normalizes blood glucose levels. SGLT2, a transport system exclusively expressed in the proximal renal tubules, mediates about 90% of renal glucose reabsorption from tubular fluid. [Definition Source: NCI]

AnnotationAssertion
abbreviated IRI: dpo:Saxagliptin

AnnotationAssertion
abbreviated IRI: dpo:Saxagliptin
literal: Saxagliptin

AnnotationAssertion
abbreviated IRI: dpo:Saxagliptin
literal: A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2S)-amino(3-hydroxyadamantan-1-yl)acetic acid with the amino group of (1S,3S,5S)-2-azabicyclo[3.1.0]hexane-3-carbonitrile. Used in its monohydrate form for the treatment of Type II diabetes. [Definition Source: CHEBI]

AnnotationAssertion
abbreviated IRI: dpo:Saxagliptin
literal: A potent, selective and competitive, cyanopyrrolidine-based, orally bioavailable inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity. Saxagliptin is metabolized into an, although less potent, active mono-hydroxy metabolite. [Definition Source: NCI]

AnnotationAssertion
abbreviated IRI: dpo:SedentaryLifestyle

AnnotationAssertion
abbreviated IRI: dpo:SedentaryLifestyle
literal: Sedentary Lifestyle

AnnotationAssertion
abbreviated IRI: dpo:SedentaryLifestyle
literal: A type of lifestyle that lacks physical exercise, characterized by sitting, reading, watching television or using a computer for much of the day without vigorous physical exertion. [Definition Source: NCI]

AnnotationAssertion
abbreviated IRI: dpo:SedentaryOccupation

AnnotationAssertion
abbreviated IRI: dpo:SedentaryOccupation
literal: Sedentary Occupation

AnnotationAssertion
abbreviated IRI: dpo:SedentaryOccupation
literal: A physical demand level described as the exertion of up to 10 pounds of force occasionally, negligible amount of work frequently, and a negligible amount of force constantly to move objects. [Definition Source: url:https://medical-dictionary.thefreedictionary.com/sedentary+work ]

AnnotationAssertion
abbreviated IRI: dpo:Semaglutide

AnnotationAssertion
abbreviated IRI: dpo:Semaglutide
literal: Semaglutide

AnnotationAssertion
abbreviated IRI: dpo:Semaglutide
literal: A polypeptide that contains a linear sequence of 31 amino acids joined together by peptide linkages. It is an agonist of glucagon-like peptide-1 receptors (GLP-1 AR) and used for the treatment of type 2 diabetes. [Definition Source: CHEBI]

AnnotationAssertion
abbreviated IRI: dpo:Sitagliptin

AnnotationAssertion
abbreviated IRI: dpo:Sitagliptin
literal: Sitagliptin

AnnotationAssertion
abbreviated IRI: dpo:Sitagliptin
literal: An orally available, competitive, beta-amino acid-derived inhibitor of dipeptidyl peptidase 4 (DDP-4) with hypoglycemic activity. Sitagliptin may cause an increased risk in the development of pancreatitis. [Definition Source: NCI]

AnnotationAssertion
abbreviated IRI: dpo:Sulfonylurea

AnnotationAssertion
abbreviated IRI: dpo:Sulfonylurea
literal: Sulfonylurea

AnnotationAssertion
abbreviated IRI: dpo:Sulfonylurea
literal: Sulfonamide urea derivatives with antihyperglycemic activity. Sulphonylurea antidiabetic agents bind to sulfonylurea receptor type 1 (SUR1), the subunit of ATP-sensitive inwardly-rectifier potassium (IKATP) channels on the membranes of pancreatic beta cells, thereby blocking the inward current flow (influx) of positively charged K+ ions into the cell. This results in tonic membrane depolarization, and induces a calcium ion influx through voltage-sensitive calcium channels; increased intracellular calcium ion levels trigger exocytosis of insulin-containing granules. This eventually induces secretion of insulin. The IKATP channels found in pancreatic islets are complexes of four IKATP 6.2 and four SUR1 subunits. In addition, some sulfonylureas of larger molecular size may increase the sensitivity of peripheral tissues to insulin mediated through peroxisome proliferator-activated receptor gamma (PPARgamma). [Definition Source: NCI]

AnnotationAssertion
abbreviated IRI: dpo:Symptom

AnnotationAssertion
abbreviated IRI: dpo:Symptom
literal: Symptom

AnnotationAssertion
abbreviated IRI: dpo:Symptom
literal: A symptom is a perceived change in function, sensation, loss, disturbance or appearance reported by a patient indicative of a disease. [ url:https://link.springer.com/chapter/10.1007/978-1-4615-4789-1_5 url:https://www.nature.com/subjects/signs-and-symptoms url:https://www.merriam-webster.com/dictionary/symptom ][Definition Source: SYMP:0000462]

AnnotationAssertion
abbreviated IRI: dpo:TestFinding
literal: A finding or categorization surmised from recorded measurements.

AnnotationAssertion
abbreviated IRI: dpo:TestFinding
literal: Test Finding

AnnotationAssertion
abbreviated IRI: dpo:TestFinding
literal: Annotation used to indicate the size or magnitude of something that was determined by comparison to a standard. [Definition Source: NCI]

AnnotationAssertion
abbreviated IRI: dpo:Therapy

AnnotationAssertion
abbreviated IRI: dpo:Therapy
literal: Therapy

AnnotationAssertion
abbreviated IRI: dpo:Therapy
literal: An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process. [Definition Source: NCI]

AnnotationAssertion
abbreviated IRI: dpo:Thiazolidinedione

AnnotationAssertion
abbreviated IRI: dpo:Thiazolidinedione
literal: Thiazolidinedione

AnnotationAssertion
abbreviated IRI: dpo:Thiazolidinedione
literal: Any antidiabetic agent with the glitazone (thiazolidinedione) base structure with antihyperglycemic activity. Glitazone antidiabetic agents selectively bind to and stimulate the nuclear receptor peroxisome proliferator-activated receptor (PPAR) gamma. This results in the selective transcription of a number of insulin-sensitive genes involved in glucose metabolism. This eventually enhances insulin sensitivity, reduces insulin resistance and decreases hepatic gluconeogenesis. PPARs function as transcription factors that regulate expressions of genes involved in cellular differentiation, development, and metabolism (carbohydrate, lipid, protein), as well as tumorigenesis; PPARgamma is expressed at high levels in adipose tissue. [Definition Source: NCI]

AnnotationAssertion
abbreviated IRI: dpo:Thing
literal: Thing

AnnotationAssertion
abbreviated IRI: dpo:TriglycerideMeasurement

AnnotationAssertion
abbreviated IRI: dpo:TriglycerideMeasurement
literal: Triglyceride Measurement

AnnotationAssertion
abbreviated IRI: dpo:TriglycerideMeasurement
literal: A quantitative measurement of the amount of triglyceride present in a sample. [Definition Source: NCI]

AnnotationAssertion
abbreviated IRI: dpo:Underweight
literal: BMI<18.5

AnnotationAssertion
abbreviated IRI: dpo:Underweight
literal: Underweight

AnnotationAssertion
abbreviated IRI: dpo:Underweight
literal: The quantification of weight/height relationships below a certain threshold that classes an individual as underweight. This threshold may vary based on an individual's ethnicity but is commonly considered in European populations to correspond to a BMI < 18. [Definition Source: EFO:0005936]

AnnotationAssertion
abbreviated IRI: dpo:UnderweightBMIRange
literal: Underweight BMI Range

AnnotationAssertion
abbreviated IRI: dpo:UnderweightBMIRange
literal: 18.5

AnnotationAssertion
abbreviated IRI: dpo:UrinarySystemSymptom
literal: A symptom involving the urinary system.

AnnotationAssertion
abbreviated IRI: dpo:UrinarySystemSymptom
literal: Urinary System Symptom

AnnotationAssertion
abbreviated IRI: dpo:UrinarySystemSymptom
literal: Symptoms of urinary disorders vary from person to person and based on the cause of the disorders. Common urinary symptoms include: Abdominal cramping; Abdominal, pelvic or back pain that can be severe; Bloody or pink-colored urine (hematuria); Cloudy urine; Fever and chills; Foul-smelling urine; Frequent urination; General ill feeling; Leaking of urine; Pain during sexual intercourse; Pain or burning with urination (dysuria); Unexplained weight loss; Urgent need to urinate. [Definition Source: url:https://www.healthgrades.com/right-care/kidneys-and-the-urinary-system/urinary-disorders ]

AnnotationAssertion
abbreviated IRI: dpo:UrinaryTractInfection

AnnotationAssertion
abbreviated IRI: dpo:UrinaryTractInfection
literal: Urinary Tract Infection (UTI)

AnnotationAssertion
abbreviated IRI: dpo:UrinaryTractInfection
literal: A bacterial infectious process affecting any part of the urinary tract, most commonly the bladder and the urethra. Symptoms include urinary urgency and frequency, burning sensation during urination, lower abdominal discomfort, and cloudy urine. [Definition Source: NCI]

AnnotationAssertion
abbreviated IRI: dpo:VeryHighLDLLevel

AnnotationAssertion
abbreviated IRI: dpo:VeryHighLDLLevel
literal: Very High LDL Level

AnnotationAssertion
abbreviated IRI: dpo:VeryHighLDLLevel

AnnotationAssertion
abbreviated IRI: dpo:VeryHighLDLRange
literal: Very High LDL Range

AnnotationAssertion
abbreviated IRI: dpo:VeryHighLDLRange
literal: 190

AnnotationAssertion
abbreviated IRI: dpo:VeryHighTriglycerideLevel

AnnotationAssertion
abbreviated IRI: dpo:VeryHighTriglycerideLevel
literal: Very High Triglyceride Level

AnnotationAssertion
abbreviated IRI: dpo:VeryHighTriglycerideLevel

AnnotationAssertion
abbreviated IRI: dpo:VeryHighTriglycerideRange
literal: Very High Triglyceride Range

AnnotationAssertion
abbreviated IRI: dpo:VeryHighTriglycerideRange
literal: 500

AnnotationAssertion
abbreviated IRI: dpo:VisionSymptom
literal: A symptom involving visual impairment.

AnnotationAssertion
abbreviated IRI: dpo:VisionSymptom
literal: Vision Symptom

AnnotationAssertion
abbreviated IRI: dpo:VisionSymptom

AnnotationAssertion
abbreviated IRI: dpo:WeightChangePotential
literal: The capacity for an increase or decrease in the weight of an individual.

AnnotationAssertion
abbreviated IRI: dpo:WeightChangePotential
literal: Weight Change Potential

AnnotationAssertion
abbreviated IRI: dpo:WeightChangePotential

AnnotationAssertion
abbreviated IRI: dpo:WeightGainPotential
literal: The capacity for an increase in the weight of an individual.

AnnotationAssertion
abbreviated IRI: dpo:WeightGainPotential
literal: Weight Gain Potential

AnnotationAssertion
abbreviated IRI: dpo:WeightGainPotential

AnnotationAssertion
abbreviated IRI: dpo:WeightLossPotential
literal: The capacity for a decrease in the weight of an individual.

AnnotationAssertion
abbreviated IRI: dpo:WeightLossPotential
literal: Weight Loss Potential

AnnotationAssertion
abbreviated IRI: dpo:WeightLossPotential

AnnotationAssertion
abbreviated IRI: dpo:hasDiagnosis
literal: has diagnosis

AnnotationAssertion
abbreviated IRI: dpo:pharmacotherapyFactor
literal: risk factor

AnnotationAssertion
abbreviated IRI: dpo:therapyFactorAversion
literal: therapy factor aversion

AnnotationAssertion
abbreviated IRI: dpo:therapyFactorIndifference
literal: therapy factor indifference

AnnotationAssertion
abbreviated IRI: dpo:therapyFactorPreference
literal: therapy factor preference

AnnotationAssertion
abbreviated IRI: sio:hasAttribute
literal: has attribute

AnnotationAssertion
IRI: http://www.ebi.ac.uk/efo/EFO_0004340
literal: body mass index

AnnotationAssertion
IRI: http://www.ebi.ac.uk/efo/EFO_0005935
literal: overweight body mass index status

AnnotationAssertion
IRI: http://www.ebi.ac.uk/efo/EFO_0005936
literal: underweight body mass index status

AnnotationAssertion
IRI: http://www.ebi.ac.uk/efo/EFO_0007041
literal: obese body mass index status